Article
Modulation of metabolic, inflammatory, fibrotic and cell death pathways by Resmetirom in metabolic dysfunction-associated steatohepatitis (MASH): A transcriptomic profiling study
2025-11-30
Abstract excerpt
Metabolic dysfunction–associated steatohepatitis (MASH) is a growing global burden with limited therapeutic options, and the mechanisms driving disease regression remain incompletely understood. Resmetirom, a selective thyroid hormone receptor-β (THR-β) agonist, has been approved for MASH, yet its molecular actions require further clarification. In this study, we employed a diet-induced mouse model of MASH using f...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7fa8f64b-869c-56af-ba4c-817e44631405
- DOI
- 10.1101/2025.11.26.690715
